Targeting NETs using dual-active DNase1 variants.

Front Immunol · 2023 · PMC10242134 · PMID 37287977

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

100%, p = 0.0360) and showed a trend towards superior degrading potential compared to DNase1 G , DNase1 K and DNase1 O mutants that each harbor mutations in an individual amino acid stretch ( Figure 3C upper gel and Figure 3D ; 100%, 113% and 103%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.